Cargando…
Chinese Proprietary Medicine Xianling Gubao Capsule for Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
OBJECTIVE: To assess the benefit and harm of Chinese medicine Xianling Gubao (XLGB) capsule compared to conventional medication or placebo to inform clinical practice. METHODS: We included randomized controlled trials (RCTs) with Jadad score ≥3 of XLGB capsule compared to pharmaceutical medication,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022208/ https://www.ncbi.nlm.nih.gov/pubmed/35464071 http://dx.doi.org/10.3389/fendo.2022.870277 |
_version_ | 1784690029137756160 |
---|---|
author | Cheng, Bai-Ru Wu, Rou-Yan Gao, Qin-Yang Jiang, Kai-Xin Li, Shuang-Sang Qi, Shi-Hao Yuan, Ming-Yi Liu, Jian-Ping |
author_facet | Cheng, Bai-Ru Wu, Rou-Yan Gao, Qin-Yang Jiang, Kai-Xin Li, Shuang-Sang Qi, Shi-Hao Yuan, Ming-Yi Liu, Jian-Ping |
author_sort | Cheng, Bai-Ru |
collection | PubMed |
description | OBJECTIVE: To assess the benefit and harm of Chinese medicine Xianling Gubao (XLGB) capsule compared to conventional medication or placebo to inform clinical practice. METHODS: We included randomized controlled trials (RCTs) with Jadad score ≥3 of XLGB capsule compared to pharmaceutical medication, placebo, or no treatment for primary osteoporosis. We conducted searches in EMBASE, Cochrane CENTRAL, MEDLINE, China National Knowledge Infrastructure, VIP, Wanfang, and Chinese Biomedical Literature Database (Sino-Med) from their inception till November 13(th), 2021. Study selection and data extraction were done by two authors independently. The methodological quality of the RCTs was assessed using Cochrane’s risk of bias tool. The effect size was presented as risk ratio (RR) or mean difference (MD) with their 95% confidence interval (CI). RESULTS: Our searches identified 2292 records and after exclusions, eight trials involving 846 participants were included. There was no statistically significant difference between conventional medications with or without XLGB on new fracture (RR: 0.50, 95% CI: [0.13, 1.87]). Quality of life by SF-36 questionnaire of XLGB plus calcium carbonate, vitamin D(3), and calcitriol was improved than that of without XLGB (MD: 6.72 scores, 95% CI: [2.82, 10.62]). XLGB increased bone mineral density similarly as calcium carbonate plus vitamin D(3) (MD: 0.21, 95% CI: [-0.16, 0.58]) or as alendronate sodium, calcium carbonate plus vitamin D(3) (MD: 0.00, 95% CI: [-0.10, 0.10]), but it had no additional effect as an add-on treatment to conventional medications (MD: 0.13, 95% CI: [-0.12, 0.37]). XLGB relieved pain via visual analog scale more effectively when combined with medications (MD: -1.55 score, 95% CI: [-2.47, -0.63]). XLGB as monotherapy did not increase adverse events (RR: 0.63, 95% CI: [0.28, 1.41]), or as an add-on treatment (RR: 0.25, 95% CI: [0.03, 2.16]). CONCLUSION: This systematic review shows that XLGB capsule appears to be safe and has a beneficial effect on the quality of life and pain relief when used alone or in combination with conventional medications in osteoporosis patients. Further large, rigorous trials are warranted to test its long-term benefit. |
format | Online Article Text |
id | pubmed-9022208 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90222082022-04-22 Chinese Proprietary Medicine Xianling Gubao Capsule for Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials Cheng, Bai-Ru Wu, Rou-Yan Gao, Qin-Yang Jiang, Kai-Xin Li, Shuang-Sang Qi, Shi-Hao Yuan, Ming-Yi Liu, Jian-Ping Front Endocrinol (Lausanne) Endocrinology OBJECTIVE: To assess the benefit and harm of Chinese medicine Xianling Gubao (XLGB) capsule compared to conventional medication or placebo to inform clinical practice. METHODS: We included randomized controlled trials (RCTs) with Jadad score ≥3 of XLGB capsule compared to pharmaceutical medication, placebo, or no treatment for primary osteoporosis. We conducted searches in EMBASE, Cochrane CENTRAL, MEDLINE, China National Knowledge Infrastructure, VIP, Wanfang, and Chinese Biomedical Literature Database (Sino-Med) from their inception till November 13(th), 2021. Study selection and data extraction were done by two authors independently. The methodological quality of the RCTs was assessed using Cochrane’s risk of bias tool. The effect size was presented as risk ratio (RR) or mean difference (MD) with their 95% confidence interval (CI). RESULTS: Our searches identified 2292 records and after exclusions, eight trials involving 846 participants were included. There was no statistically significant difference between conventional medications with or without XLGB on new fracture (RR: 0.50, 95% CI: [0.13, 1.87]). Quality of life by SF-36 questionnaire of XLGB plus calcium carbonate, vitamin D(3), and calcitriol was improved than that of without XLGB (MD: 6.72 scores, 95% CI: [2.82, 10.62]). XLGB increased bone mineral density similarly as calcium carbonate plus vitamin D(3) (MD: 0.21, 95% CI: [-0.16, 0.58]) or as alendronate sodium, calcium carbonate plus vitamin D(3) (MD: 0.00, 95% CI: [-0.10, 0.10]), but it had no additional effect as an add-on treatment to conventional medications (MD: 0.13, 95% CI: [-0.12, 0.37]). XLGB relieved pain via visual analog scale more effectively when combined with medications (MD: -1.55 score, 95% CI: [-2.47, -0.63]). XLGB as monotherapy did not increase adverse events (RR: 0.63, 95% CI: [0.28, 1.41]), or as an add-on treatment (RR: 0.25, 95% CI: [0.03, 2.16]). CONCLUSION: This systematic review shows that XLGB capsule appears to be safe and has a beneficial effect on the quality of life and pain relief when used alone or in combination with conventional medications in osteoporosis patients. Further large, rigorous trials are warranted to test its long-term benefit. Frontiers Media S.A. 2022-04-07 /pmc/articles/PMC9022208/ /pubmed/35464071 http://dx.doi.org/10.3389/fendo.2022.870277 Text en Copyright © 2022 Cheng, Wu, Gao, Jiang, Li, Qi, Yuan and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Cheng, Bai-Ru Wu, Rou-Yan Gao, Qin-Yang Jiang, Kai-Xin Li, Shuang-Sang Qi, Shi-Hao Yuan, Ming-Yi Liu, Jian-Ping Chinese Proprietary Medicine Xianling Gubao Capsule for Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
title | Chinese Proprietary Medicine Xianling Gubao Capsule for Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
title_full | Chinese Proprietary Medicine Xianling Gubao Capsule for Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
title_fullStr | Chinese Proprietary Medicine Xianling Gubao Capsule for Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
title_full_unstemmed | Chinese Proprietary Medicine Xianling Gubao Capsule for Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
title_short | Chinese Proprietary Medicine Xianling Gubao Capsule for Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
title_sort | chinese proprietary medicine xianling gubao capsule for osteoporosis: a systematic review and meta-analysis of randomized clinical trials |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022208/ https://www.ncbi.nlm.nih.gov/pubmed/35464071 http://dx.doi.org/10.3389/fendo.2022.870277 |
work_keys_str_mv | AT chengbairu chineseproprietarymedicinexianlinggubaocapsuleforosteoporosisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT wurouyan chineseproprietarymedicinexianlinggubaocapsuleforosteoporosisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT gaoqinyang chineseproprietarymedicinexianlinggubaocapsuleforosteoporosisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT jiangkaixin chineseproprietarymedicinexianlinggubaocapsuleforosteoporosisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT lishuangsang chineseproprietarymedicinexianlinggubaocapsuleforosteoporosisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT qishihao chineseproprietarymedicinexianlinggubaocapsuleforosteoporosisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT yuanmingyi chineseproprietarymedicinexianlinggubaocapsuleforosteoporosisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT liujianping chineseproprietarymedicinexianlinggubaocapsuleforosteoporosisasystematicreviewandmetaanalysisofrandomizedclinicaltrials |